Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 88 of 121 for:    prostate cancer AND prostate cancer screening | ( Map: United States )

Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02771769
Recruitment Status : Recruiting
First Posted : May 13, 2016
Last Update Posted : April 9, 2018
Sponsor:
Collaborators:
Smerud Medical Research International AS
Vanderbilt University
Information provided by (Responsible Party):
Chronix Biomedical Corporation

Tracking Information
First Submitted Date May 10, 2016
First Posted Date May 13, 2016
Last Update Posted Date April 9, 2018
Study Start Date January 2016
Estimated Primary Completion Date November 1, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: May 11, 2016)
CNI correlation with biopsy [ Time Frame: Through completion of study and all data analysis which may take up to 2 years. ]
To determine if copy number instability (CNI scores) derived from analysis of cell-free cancer DNA (cfDNA) in patients undergoing prostate biopsy correlates with biopsy diagnosis of prostate cancer.
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT02771769 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: May 11, 2016)
  • CNI correlation with BPH [ Time Frame: Through completion of study and all data analysis which may take up to 2 years. ]
    To determine if copy number instability (CNI scores) derived from analysis of cell-free DNA (cfDNA) in patients undergoing prostate biopsy can distinguish between biopsy diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer.
  • CNI correlation with PIN [ Time Frame: Through completion of study and all data analysis which may take up to 2 years. ]
    To determine if copy number instability (CNI scores) derived from analysis of cell-free DNA (cfDNA) in patients undergoing prostate biopsy correlates with measured evidence of prostatic intraepithelial neoplasia (PIN).
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
Official Title A Multi-center Prospective Study to Analyze Cancer-derived Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
Brief Summary This is a multi-centre prospective study in which blood samples will be taken from 1500 male patients aged between 21-80 scheduled for prostate biopsy. Analysis of cell-free cancer DNA extracted from these samples will be undertaken to determine whether copy number instability scores derived from the cfDNA correlates with PSA screening levels and prostate biopsy results (i.e. Gleason score) in these patients.
Detailed Description

The prostate is the most common site of cancer in men with 240,000 new cases diagnosed annually in the United States with approximately 28,000 yearly deaths. Prostate screening typically relies on digital rectal exam (DRE) and prostate specific antigen (PSA) levels. Limitations of the PSA test include its low sensitivity and low specificity and its inability to distinguish between low-grade and high-grade lesions. Recent screening trials suggest that PSA-based screening programs result in small or no reduction in mortality, and have significant treatment-related adverse events (AEs). Better serum/plasma biomarkers are needed to supplement the PSA test in the diagnosis and management of a disease with a multiplicity of presentations and clinical outcomes.

Cancer-derived DNA present in peripheral blood (referred to as cell-free DNA or cfDNA) was first reported in 1948, but research into this area remained in a dormant state for over 50 years. Over the last ten years however, the development of Next Generation Sequencing (NGS) using massive parallel arrays has allowed researchers to create a database robust enough to distinguish normal genomic from non-diploid cfDNA. In 2008, fetal trisomy of chromosome 21 was detected by analyzing cfDNA in maternal blood. Since then, the method has been validated for trisomy 13, 18, and 21 as a clinical laboratory procedure with remarkable accuracy >99%. Recently, cancer derived cfDNA has been demonstrated to recapitulate genomic tumor DNA. Current clinical acceptance of the utility of cfDNA in cancer diagnosis has been demonstrated in multiple abstracts at the 2014 and 2015 ASCO meetings in Chicago.

In a recent publication in Clinical Chemistry, researchers at Vanderbilt University, Gottingen, Germany, and at the University of Toronto, Canada, analyzed cfDNA in the bloodstream from healthy controls as compared to those with clinically diagnosed prostate cancer. The results of this study demonstrated that it is possible to distinguish prostate cancer from healthy controls without prior knowledge of the genetic signature of the tumors and with over three times the sensitivity of the FDA-approved blood test for prostate cancer (i.e., prostate-specific antigen (PSA)). The study examined serum from more than 200 subjects with prostate cancer and more than 200 controls. The comparative data included PSA levels and prostate tissue biopsy grading (referred to as the Gleason score). The technique distinguished prostate cancer from normal controls with 84% accuracy and cancer from benign hyperplasia and prostatitis with an accuracy of 91%. Because the method quantifies the inherent chromosomal instability of cancer and can be followed as a function of time (without having to do an invasive tissue biopsy), it is called a "liquid biopsy." This multi-centre clinical study will analyze cfDNA from subjects scheduled for prostate biopsy and is designed to validate the results obtained in the above-mentioned retrospective study. If validated, the prostate cfDNA determination test will provide a non-invasive test to aid in the diagnosis of prostate cancer, as well as provide guidance on whether a biopsy should be performed.

With regard to the study procedures used, the study subject will undergo routine venipuncture and ~20 millilitres of blood (approximately 2 tablespoons) will be collected. The blood will then be processed by the Sponsor's laboratory and sent to the Sponsor's testing facility in Gottingen, Germany.

Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Cell-free and cell-associated DNA will be obtained from plasma and peripheral blood mononuclear cells, respectively. DNA will be stored until study is completed and data are published.
Sampling Method Non-Probability Sample
Study Population Male subjects between the ages of 21-80 who are scheduled for a prostate biopsy and meet one of the eligibility criteria listed below.
Condition Prostatic Neoplasms
Intervention Other: blood draw
Participants will have a venous blood draw of ~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: May 11, 2016)
1500
Original Estimated Enrollment Same as current
Estimated Study Completion Date April 1, 2019
Estimated Primary Completion Date November 1, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Who, in the opinion of the site Investigator, have an abnormal PSA level as measured by a CLIA certified laboratory or non-USA equivalent within the last 60 days, and/or
  2. Who, in the opinion of the site Investigator, have an abnormal digital rectal examination

Exclusion Criteria:

  1. Male subjects with active or historical histologically confirmed diagnosis of malignancy
  2. Male subjects who have participated in a clinical trial involving an investigational drug within the 28 days prior to signing the informed consent form
Sex/Gender
Sexes Eligible for Study: Male
Ages 21 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Jessica B Collins, BA 1-615-343-6485 jessica.collins@vanderbilt.edu
Contact: David A McKeel, BA 1-615-343-6485 david.a.mckeel@vanderbilt.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT02771769
Other Study ID Numbers CHX-2015-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD: Yes
Plan Description: Participants may request data upon writing to their physician. Data will not be available until after publication of data.
Responsible Party Chronix Biomedical Corporation
Study Sponsor Chronix Biomedical Corporation
Collaborators
  • Smerud Medical Research International AS
  • Vanderbilt University
Investigators
Principal Investigator: David F Penson, MD Vanderbilt University
PRS Account Chronix Biomedical Corporation
Verification Date April 2018